MedPath

Simvastatin Therapy in Women With Polycystic Ovary Syndrome.

Not Applicable
Completed
Conditions
Polycystic Ovary Syndrome
Registration Number
NCT00365638
Lead Sponsor
Poznan University of Medical Sciences
Brief Summary

The purpose of this study is to determine whether statins (simvastatin) improve clinical (excessive hair, skin problems), endocrine (androgens) and metabolic (lipids, markers of systemic inflammation) in women with polycystic ovary syndrome (PCOS).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria
  • PCO - ESHRE/ASRM criteria: oligomenorrhea (<8 spontaneous menses per year) and hyperandrogenism (hirsutism or acne) or hyperandrogenemia (testosterone >70ng/dl)
  • Normal prolactin, TSH, 17-OH progesterone
  • No evidence of androgen producing malignancy, Cushing's syndrome or acromegaly
  • Age 18-40
  • Reliable use of birth control pill for at least 3 months and no plans of pregnancy
Exclusion Criteria
  • Elevated creatinine kinase above 2 times upper limit of normal or liver enzymes (transaminases) above 2 times of upper limit of normal
  • Use of any of the following medications: cyclosporine, fibrates, niacin, antifungal agents, macrolide antibiotics.
  • Use of oral contraceptives and other steroid hormones 3 months prior to the study
  • Contraindications to oral contraceptives

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
serum testosterone
Secondary Outcome Measures
NameTimeMethod
serum lutropin
serum follitropin
serum lipids
serum DHEA-S
serum SHBG
serum insulin

Trial Locations

Locations (1)

Division of Infertility and Reproductive Endocrinology, Department of Gynecology and Obsterics

🇵🇱

Poznan, Poland

© Copyright 2025. All Rights Reserved by MedPath